GENFIT Reports €9.6M Revenue Boost on Iqirvo Royalties, Extends Cash Runway to 2028
Event summary
- GENFIT reported €9.6M revenue in Q1 2026, up from €2.8M in Q1 2025, driven by Iqirvo royalties.
- Cash position grew to €136.1M as of March 31, 2026, with runway extended beyond 2028.
- Ipsen's Iqirvo sales reached €78.8M in Q1 2026, triggering a €17M milestone payment.
- NASHnext diagnostic test launch imminent, with Medicare/Medicaid pricing framework established.
- Phase 1b data for GNS561 in cholangiocarcinoma expected mid-2026.
The big picture
GENFIT's Q1 2026 results highlight the company's dual revenue streams from Iqirvo royalties and emerging MASH diagnostics, supported by solid regulatory and commercial execution. The €30M royalty financing tranche enhances financial flexibility without shareholder dilution, while Ipsen's accelerated Iqirvo sales demonstrate market validation. GENFIT's strategic focus on high-risk clinical programs positions it for potential significant value creation if successful.
What we're watching
- Revenue Momentum
- Whether Iqirvo's accelerated sales trajectory in the US and Europe can sustain GENFIT's royalty revenue growth.
- Diagnostic Market
- The pace at which NASHnext gains payer adoption following its commercial launch and Medicare pricing framework establishment.
- Clinical Pipeline
- How Phase 1b data for GNS561 and NTZ/G1090N will impact GENFIT's high-risk, high-reward clinical programs.
Related topics